Benefit of selinexor dose reduction on outcomes with selinexor, bortezomib and dexamethasone in patients with lenalidomide-refractory multiple myeloma: Subgroup analysis of the BOSTON trial.
Saved in:
| Title: | Benefit of selinexor dose reduction on outcomes with selinexor, bortezomib and dexamethasone in patients with lenalidomide-refractory multiple myeloma: Subgroup analysis of the BOSTON trial. |
|---|---|
| Authors: | Delimpasi S; Evangelismos Hospital, Athens, Greece., Špička I; First Department of Medicine, Department of Hematology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic., Butler JP; Bone Marrow Transplant Unit, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia., Stevens DA; Norton Cancer Institute, Louisville, Kentucky, USA., Mesa MG; Department of Hematology, Hospital Universitari Vall d'Hebron, Barcelona, Spain., Bygrave C; University Hospital of Wales, Cardiff, UK., Merlo GM; Menarini Group, Florence, Italy., la Porte C; Menarini Group, Machelen, Belgium., Dimopoulos MA; Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Alexandra Hospital, Athens, Greece.; Department of Medicine, Korea University, Seoul, South Korea. |
| Source: | British journal of haematology [Br J Haematol] 2026 Jun; Vol. 208 (6), pp. 2260-2264. Date of Electronic Publication: 2026 Apr 14. |
| Publication Type: | Journal Article; Clinical Trial, Phase III |
| Journal Info: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 0372544 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2141 (Electronic) Linking ISSN: 00071048 NLM ISO Abbreviation: Br J Haematol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 41978554 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Benefit of selinexor dose reduction on outcomes with selinexor, bortezomib and dexamethasone in patients with lenalidomide-refractory multiple myeloma: Subgroup analysis of the BOSTON trial. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Delimpasi+S%22">Delimpasi S</searchLink>; Evangelismos Hospital, Athens, Greece.<br /><searchLink fieldCode="AU" term="%22Špička+I%22">Špička I</searchLink>; First Department of Medicine, Department of Hematology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.<br /><searchLink fieldCode="AU" term="%22Butler+JP%22">Butler JP</searchLink>; Bone Marrow Transplant Unit, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia.<br /><searchLink fieldCode="AU" term="%22Stevens+DA%22">Stevens DA</searchLink>; Norton Cancer Institute, Louisville, Kentucky, USA.<br /><searchLink fieldCode="AU" term="%22Mesa+MG%22">Mesa MG</searchLink>; Department of Hematology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Bygrave+C%22">Bygrave C</searchLink>; University Hospital of Wales, Cardiff, UK.<br /><searchLink fieldCode="AU" term="%22Merlo+GM%22">Merlo GM</searchLink>; Menarini Group, Florence, Italy.<br /><searchLink fieldCode="AU" term="%22la+Porte+C%22">la Porte C</searchLink>; Menarini Group, Machelen, Belgium.<br /><searchLink fieldCode="AU" term="%22Dimopoulos+MA%22">Dimopoulos MA</searchLink>; Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Alexandra Hospital, Athens, Greece.; Department of Medicine, Korea University, Seoul, South Korea. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%220372544%22">British journal of haematology</searchLink> [Br J Haematol] 2026 Jun; Vol. 208 (6), pp. 2260-2264. <i>Date of Electronic Publication: </i>2026 Apr 14. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Clinical Trial, Phase III – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wiley-Blackwell%22">Wiley-Blackwell </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>0372544 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1365-2141 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200071048%22">00071048 </searchLink><i>NLM ISO Abbreviation: </i>Br J Haematol <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41978554 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1111/bjh.70479 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 2260 Titles: – TitleFull: Benefit of selinexor dose reduction on outcomes with selinexor, bortezomib and dexamethasone in patients with lenalidomide-refractory multiple myeloma: Subgroup analysis of the BOSTON trial. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Delimpasi S – PersonEntity: Name: NameFull: Špička I – PersonEntity: Name: NameFull: Butler JP – PersonEntity: Name: NameFull: Stevens DA – PersonEntity: Name: NameFull: Mesa MG – PersonEntity: Name: NameFull: Bygrave C – PersonEntity: Name: NameFull: Merlo GM – PersonEntity: Name: NameFull: la Porte C – PersonEntity: Name: NameFull: Dimopoulos MA IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 06 Text: 2026 Jun Type: published Y: 2026 Identifiers: – Type: issn-electronic Value: 1365-2141 Numbering: – Type: volume Value: 208 – Type: issue Value: 6 Titles: – TitleFull: British journal of haematology Type: main |
| ResultId | 1 |
